skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi, great job my portfolio is up, thanks.
I bought GUD for sector, management, cash position, growth (safety) etc.
They finally made an acquisition which looks ok.(no homerun?) still down ,bought at $8.50
Looks like an important quarter in March,if it is good all should be ok, if not ,it will not have the big cash backstop that it did in the past. Won’t this be a problem?
Getting a little impatient, if it is only a so-so or down quarter, is it not time to seriously consider an alternative? Or would you give it “another”3-5 years?
Thanks,
Read Answer Asked by Brad on February 19, 2020
Q: I was surprised to see Park Lawn go down over 5 percent today on the announcement of the ceo's departure. When i looked into it a little closer, i saw that Mr. Clark had taken a small company worth 30 million to one evaluated at over 900 million in just seven years. I see Mr. Paul Smith is filling in as chairman while they search for a new ceo. Is it odd that in that time they did not hire someone and groome them for the post? I can see the importance of leadership! Should we be worried with this transition?
Read Answer Asked by joseph on February 18, 2020
Q: Your recent report on KXS notes that the expected F2020 revenue growth is 11.1% and a CIBC report forecasts revenue growth of 17% in F2021. Both these estimates are below the expected F2019 revenue growth of 26% and lower than the 22.4% forecasted annual growth rate (to 2022) of the SaaS application market in supply chain management. In such a competitive market, forecasts of declines in revenue growth and forecasted growth which is lower than the market’s growth are not ideal signs and something to monitor. Have you picked up any explanations for the decline in forecasted revenue growth in F2020 and the overall choppiness of revenue growth?
Read Answer Asked by Marc on February 18, 2020
Q: Thanks for your reply to my Knight Therapeutics question. Can you be more specific about
two parts:
1) Do small shareholders in GBT have to sell?
2) The stock price is surprisingly weak - do you think medisen is selling now to fund their share re-purchase or can you speculate any reason why selling is going on now after waiting so long for a big, non-dilutive cash purchase? It is a big surprise to me.
That's it.
Thank you.
Read Answer Asked by Steven on February 14, 2020
Q: I haven't seen too many company purchases similar to GUD buying GBT. Is it unusual to take out the major shareholders then individuals and will small shareholders be forced to sell?
The purchase was paid in cash with no dilution, Medisen is paying $77M for their shares, GUD will have well over $300M left plus any Biotoscana profits from Nov. 29 and, yet the share price is very weak. Is something not going well?
Finally, Medisen has 4 years to sell their GUD shares. Do you think they are selling now to raise cash to buy back their shares and, second, is a low price good for GUD as biotoscan shareholders will most likely sell at the ptemium offered? Thank you!
Read Answer Asked by Steven on February 14, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!